Defined Probiotic Strain Mixtures for Sustained IBS Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for gastrointestinal disorders such as irritable bowel syndrome (IBS) and chronic inflammatory bowel diseases (IBD) do not provide a complete and lasting resolution of symptoms, and the effectiveness of probiotic bacterial strains remains unclear.
Innovation Solution
The use of novel bacterial strains, including Bifidobacterium breve BbIBS01, Bifidobacterium breve BbIBS02, Bifidobacterium animalis subsp. lactis BlIBS01, and Lactobacillus plantarum LpIBS01, and their derivatives, as well as mixtures with other strains like Bifidobacterium bifidum MIMBb23sg, Lactobacillus casei DG®, and Lactobacillus paracasei LPC-S01™, to modulate gut microbiota, increase beneficial bacteria, reduce pathobionts, and regulate immune responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for gastrointestinal disorders are used, then symptoms may be temporarily managed, but complete and lasting resolution is not achieved
Solution Approach 1:
The patent introduces specific probiotic bacterial strains (Bifidobacterium breve BbIBS01, Bifidobacterium breve BbIBS02, Bifidobacterium animalis subsp. lactis BlIBS01, and Lactobacillus plantarum LpIBS01) that are administered in advance to prevent and treat gastrointestinal disorders before they fully develop or recur, thereby achieving lasting therapeutic effects rather than temporary symptom management
Solution Approach 2:
The patent changes the therapeutic parameter from conventional treatments to specifically selected probiotic strains with proven efficacy, altering the biological composition of the gut microbiota to achieve sustained remission of gastrointestinal symptoms
2Adaptability or versatility
If probiotic bacterial strains are used to treat gastrointestinal disorders, then gut microbiota may be modulated, but the effectiveness of specific strains remains unclear
Solution Approach 1:
The patent segments the broad category of probiotics into specific, individually identified bacterial strains (BbIBS01, BbIBS02, BlIBS01, LpIBS01) with documented efficacy for gastrointestinal disorders, allowing precise measurement and verification of each strain's effectiveness rather than using undefined probiotic mixtures
Solution Approach 2:
The patent employs clinical evaluation and monitoring of patients receiving these specific probiotic strains to verify their effectiveness in treating gastrointestinal disorders, creating a feedback loop that confirms strain performance and guides further application
Data Source
AI summary
Compositions comprising a mixture comprising the bacterial strain Bifidobacterium bifidum MIMBb23sg or BbfIBS01 (DSM 32708), at least one or more bacterial strains selected from group A comprising the strains B. breve BbIBS01 (DSM 33231), B. breve BbIBS02 (DSM 33232), B. animalis subsp. lactis BlIBS01 (DSM 33233) and L. plantarum LpIBS01 (DSM 33234) and, optionally, at least one further bacterial strain selected from a bacterial strain L. casei DG® (CNCM I-1572) and a bacterial strain L. paracasei LPC-S01™ (DSM 26760) and related method for the treatment of gastrointestinal diseases, disorders or symptoms, in particular functional gastrointestinal disorders, such as, for example irritable bowel syndrome (IBS) are described.